Preclinical News and Research

RSS
RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

MicuRx Pharmaceuticals, Cumencor Pharmaceuticals, Pfizer collaborate to develop antibiotics for MDR-TB

MicuRx Pharmaceuticals, Cumencor Pharmaceuticals, Pfizer collaborate to develop antibiotics for MDR-TB

PS-targeting antibodies can block HIV virus from entering into certain blood cells

PS-targeting antibodies can block HIV virus from entering into certain blood cells

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing

Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

Clinical utility and pharmacological action of MN-166 in treatment of MS

Clinical utility and pharmacological action of MN-166 in treatment of MS

Cellvax moves to new laboratory facility in ENVA

Cellvax moves to new laboratory facility in ENVA

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer

"Mouse model" study finds LRRK2 gene mutation may cause inherited Parkinson's disease

"Mouse model" study finds LRRK2 gene mutation may cause inherited Parkinson's disease

NAFC supports PMAA of Uromedica's ACT device for SUI, speaks to FDA

NAFC supports PMAA of Uromedica's ACT device for SUI, speaks to FDA

Elsevier adds extensive FDA Advisory Committee content to new PharmaPendium

Elsevier adds extensive FDA Advisory Committee content to new PharmaPendium

Cyclacel Pharmaceuticals' abstracts on cell cycle inhibitor drugs selected for presentation at AACR meeting

Cyclacel Pharmaceuticals' abstracts on cell cycle inhibitor drugs selected for presentation at AACR meeting

Ricerca Biosciences, Life Science Partner announce business development agreement

Ricerca Biosciences, Life Science Partner announce business development agreement

BELLUS Health initiates Phase I clinical study for NRM8499

BELLUS Health initiates Phase I clinical study for NRM8499

Insight into how mutations in LRRK2 gene may cause familial Parkinson's disease

Insight into how mutations in LRRK2 gene may cause familial Parkinson's disease

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

LAB Research reports 9% decrease in revenues for 2009

LAB Research reports 9% decrease in revenues for 2009

Major breakthrough may help develop low toxicity drugs for sleeping sickness

Major breakthrough may help develop low toxicity drugs for sleeping sickness

RXi Pharmaceuticals reports net loss of 28% for 2009

RXi Pharmaceuticals reports net loss of 28% for 2009

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.